Farmacia Hospitalaria y Farmacogenómica

García-Moreno FJ; Escobar-Castellanos M; Marañón R; Rivas-García A; Manrique-Rodríguez S; Mora-Capín A; Fernández-Llamazares CM.

Adecuacy of pediatric antimicrobial prescribing in the Emergency Department at discharge.

Anales De Pediatria. 2022; 96(3): 179-189 [doi:10.1016/j.anpede.2020.11.015]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Clinical & Translational Oncology. 2022; 24(3): 483-494 Nº de citas: 49 [doi:10.1007/s12094-021-02708-4]

Narrillos-Moraza, A; Gomez-Martinez-Sagrera, P; Amor-Garcia, MA; Escudero-Vilaplana, V; Collado-Borrell, R; Villanueva-Bueno, C; Gomez-Centurion, I; Herranz-Alonso, A; Sanjurjo-Saez, M.

Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale

JMIR mHealth and uHealth. 2022; 10(2): Nº de citas: 23 [doi:10.2196/32826]

Villanueva-Bueno C; Montecatine-Alonso E; Jiménez-Parrilla F; Fernández-Llamazares CM; Manrique-Rodríguez S; Zamora-Flores E; Dolz E; Fernández-Polo A; Catillo-Salinas F; Comuñas J; Gallego-Fernández C; González-López M; Gómez-Trevecedo Calvo MT; Gázquez-Pérez R; Álvarez Del Vayo-Benito C; Gil-Navarro MV.

Antimicrobial defined daily dose in neonatal population.

Enfermedades Infecciosas Y Microbiologia Clinica (english Ed.). 2022; 40(2): 59-65 [doi:10.1016/j.eimce.2021.05.012]

Enriquez-Gomez, A; Ortega-Navarro, C; Fernandez-Cordon, C; Diez-Villanueva, P; Martinez-Selles, M; de Lorenzo-Pinto, A; de Miguel-Yanes, JM.

Comparison of a polypharmacy-based scale with Charlson comorbidity index to predict 6-month mortality in chronic complex patients after an ED visit

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2022; 88(4): 1795-1803 Nº de citas: 4 [doi:10.1111/bcp.15096]

Vicente-Valor, J; Garcia-Gonzalez, X; Ibanez-Garcia, S; Duran-Garcia, ME; de Lorenzo-Pinto, A; Rodriguez-Gonzalez, C; Mendez-Fernandez, I; Percovich-Hualpa, JC; Herranz-Alonso, A; Sanjurjo-Saez, M.

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

BIOMEDICINE & PHARMACOTHERAPY. 2022; 146: 112519-112519 Nº de citas: 24 [doi:10.1016/j.biopha.2021.112519]

Villanueva-Bueno, C; Montecatine-Alonso, E; Jimenez-Parrilla, F; Fernandez-Llamazares, CM; Manrique-Rodriguez, S; Zamora-Flores, E; Dolz, E; Fernandez-Polo, A; Catillo-Salinas, F; Comunas, J; Gallego-Fernandez, C; Gonzalez-Lopez, M; Calvo, MTGT; Gazquez-Perez, R; del Vayo-Benito, CA; Gil-Navarro, MV; Paediat Antimicrobial Defined Dail.

Antimicrobial defined daily dose in neonatal population

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2022; 40(2): 59-65 Nº de citas: 8 [doi:10.1016/j.eimc.2021.05.007]

Gil-Manso, S; Blanco, IM; Lopez-Esteban, R; Carbonell, D; Lopez-Fernandez, LA; West, L; Correa-Rocha, R; Pion, M.

Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals

Frontiers in Immunology. 2022; 12: 793142-793142 Nº de citas: 22 [doi:10.3389/fimmu.2021.793142]

Villanueva-Bueno, C; Escudero-Vilaplana, V; Collado-Borrell, R; Gimenez-Manzorro, A; Ribed, A; Marzal-Alfaro, B; Revuelta-Herrero, JL; Gonzalez-Haba, E; Herranz, A; Sanjurjo, M.

Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

Expert Opinion On Drug Safety. 2022; 21(1): 107-119 Nº de citas: 7 [doi:10.1080/14740338.2021.1965990]

Gomez-Centurion, I; Oarbeascoa, G; Garcia, MC; Fresnena, MCL; Carreno, MJM; Vilaplana, VE; Gonzalez-Haba, E; Bailen, R; Dorado, N; Juarez, LM; Macias, GR; Lopez, PF; Encinas, C; Bastos-Oreiro, M; Anguita, J; Sanjurjo, M; Diez-Martin, JL; Kwon, M.

Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

INTERNATIONAL JOURNAL OF HEMATOLOGY. 2022; 115(1): 61-68 Nº de citas: 16 [doi:10.1007/s12185-021-03219-2]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

Expert Opinion on Drug Metabolism & Toxicology. 2022; 17(12): 1467-1473 Nº de citas: 11 [doi:10.1080/17425255.2021.2027908]

Martinez, CLC; Jimenez, RMR; Vazquez-Lopez, C; Perez-Cordon, L; Hidalgo, SV; Jose, PB.

Recommendations for using oral antineoplastic and immunomodulating agents in oncohematology by enteral tube administration

Nutricion Hospitalaria. 2022; 39(1): 171-201 Nº de citas: 8 [doi:10.20960/nh.03736]

Soria-Chacartegui, P; Villapalos-Garcia, G; Lopez-Fernandez, LA; Navares-Gomez, M; Mejia-Abril, G; Abad-Santos, F; Zubiaur, P.

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study

Pharmaceutics. 2021; 13(12): Nº de citas: 12 [doi:10.3390/pharmaceutics13122036]

GARCÍA, X.; SALVADOR, S..

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal of Personalized Medicine. 2021; : [doi:https://doi.org/10.3390/jpm11111180]

Salvador-Martin, S; Melgarejo-Ortuno, A; Lopez-Fernandez, LA.

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): Nº de citas: 6 [doi:10.3390/pharmaceutics13111786]

García-González X; Salvador-Martín S.

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal of Personalized Medicine. 2021; 11(11): Nº de citas: 7 [doi:10.3390/jpm11111180]

Morillo Verdugo R; Calvin Lamas M; Delgado Latorre ATJ; Ferrando Piqueres R; Fernández-Llamazares CM; Negro Vega E; Tortajada Goitia B.

Development of the Q-PEX standard for quality certification of pharmaceutical care for outpatients of Pharmacy services

Journal of Healthcare Quality Research. 2021; 36(6): 324-332 Nº de citas: 16 [doi:10.1016/j.jhqr.2021.03.010]

SALVADOR, S.; MELGAREJO, A.; LOPEZ, L..

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): [doi:https://doi.org/10.3390/pharmaceutics13111786]